
College grads face a 'tough and competitive' job market this year, expert says
A graduating student of the CCNY wears a message on his cap during the College's commencement ceremony.
Mike Segar | Reuters
New college graduates looking for work now are finding a tighter labor market than they expected even a few months ago.
The unemployment rate for recent college grads reached 5.8% in March, up from 4.6% the same time a year ago, according to an April report from the Federal Reserve Bank of New York.
Job postings at Handshake, a campus recruiting platform, are down 15% over the past year, while the number of applications has risen by 30%.
Christine Cruzvergara, chief education strategy officer at Handshake, says new grads are finding a 'tough and competitive' market.
'There's a lot of uncertainty and certainly a lot of competition for the current graduates that are coming into the job market,' she said.
Here's a look at more stories on how to manage, grow and protect your money for the years ahead. How federal job cuts hurt the Class of 2025
While the job creation in the U.S. has continued to show signs of strength, policy changes have driven the uncertainty.
President Donald Trump has frozen federal hiring and done mass firings of government workers. Evercore ISI, an investment bank, estimated earlier this month that 350,000 federal workers have been impacted by cuts from Department of Government Efficiency, representing roughly 15% of federal workers, with layoffs set to take effect over the coming months.
'In early January, the class of 2025 was on track to meet and even exceed the number of applications to federal government jobs,' Cruzvergara said. When the executive orders hit in mid-January there was 'a pretty steep decline all of a sudden, she said.
'The federal government is one of the largest employers in this country, and also one of the largest employers for entry-level employees as well,' said Loujaina Abdelwahed, senior economist at Revelio Labs, a workforce intelligence firm. Employment uncertainty related to tariffs, AI
On-again, off-again tariff policies have created uncertainty for companies, with a third of chief executive officers in a recent CNBC survey expecting to cut jobs this year because of the import taxes.
Job losses from artificial intelligence technology are also a concern.
A majority, 62%, of the Class of 2025 are concerned about what AI will mean for their jobs, compared to 44% two years ago, according to a survey by Handshake. Graduates in the humanities and computer science are the most worried about AI's impact on jobs.
'I think it's more about a redefinition of the entry level than it is about an elimination of the entry level,' Cruzvergara said.
Postings for jobs in hospitality, education services, and sales were showing monthly growth through March, according to Revelio Labs. But almost all industries, with the exception of information jobs, saw pullbacks in April. How to land a job in a tough market
For new grads hunting for a job, experts advise keeping a positive mindset.
'Employers don't want to hire someone that they feel like is desperate or bitter or upset,' said Cruzvergara. 'They want to hire someone that still feels like there's a lot of opportunity, there's a lot of potential.'
Here are two tactics that can help with your search: 1. Look at small firms — they may provide big opportunities
Companies with fewer than 250 employees may offer better opportunities to grow and learn than bigger 'brand name' firms, according to Revelio Labs.
A new study by Revelio found that five years into their careers, graduates had comparable salary progression, promotion timelines, and managerial prospects — regardless of the size of their first employer. However, people who started their careers at small companies were 1.5 times more likely to become founders of their own companies later in their careers.
The study looked at individuals who earned bachelor's degrees in the U.S. between 2015 and 2022, following their career paths post-graduation.
While some young workers may have entered start-ups with the goal of starting their own firm in the future, Abdelwahed said there's often an opportunity at smaller companies to be given responsibilities beyond the job's role.
'Because the company's small and the work needs to get done, so they just start to develop this entrepreneurship drive,' Abdelwahed said. 2. Network and use informational interviews
Experts also urge recent grads to reach out to people working in industries that pique their interest.
'Take an interest in someone else. Ask them questions about how they got to where they are, what they've learned, what you should know about that particular industry, what are emerging trends or issues that are facing them in the field right now,' said Cruzvergara.
This approach can help you sound more knowledgeable in the application and interviewing process.
— CNBC's Sharon Epperson contributed reporting.
SIGN UP: Money 101 is an 8-week learning course on financial freedom, delivered weekly to your inbox. Sign up here. It is also available in Spanish.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio


Bloomberg
20 hours ago
- Bloomberg
Will the Class of 2025 Ever Get Over College?
This is Bloomberg Opinion Today, a US asset that generates tens or even hundreds of billions of dollars of economic value for Bloomberg Opinion's opinions. On Sundays, we look at the major themes of the week past and how they will define the week ahead. Sign up for the daily newsletter here. 'Looking back over a decade,' wrote F. Scott Fitzgerald, an indifferent student if there ever was one, 'one sees the ideal of a university become a myth, a vision, a meadow lark among the smoke stacks.' I'm wondering what image the class of 2025 will see in 2035 as they look back on their remarkably tumultuous undergraduate years. Will it be standing in defiance of administrators and politicians and police forces in a peaceful exercise of their First Amendment rights? Or standing in support of terrorists who murdered hundreds of people their age at a trance concert?


Business Upturn
21 hours ago
- Business Upturn
RailTel partners with Techno Electric to set ip 10MW Data Centre in Noida
By Aman Shukla Published on June 1, 2025, 15:34 IST RailTel Corporation of India Ltd. has announced the selection of M/s Techno Electric & Engineering Co. Ltd. (TECL) as its Managed Service Data Centre Partner. This strategic partnership, finalized through an open tender process, involves the development of a 10MW Data Centre in phases on RailTel's land located in Noida. A Letter of Intent (LOI) has already been issued to TECL, marking the commencement of this long-term collaboration. Under the terms of the LOI, TECL will develop the Data Centre in phases on land provided by RailTel in Noida. RailTel will receive a share of the revenue generated from the operations of the Data Centre, calculated on a fixed percentage basis. The duration of the agreement is 30 years, including the implementation phase, with the possibility of extension through mutual consent. As the agreement is structured around future earnings, the financial value of the contract cannot be precisely quantified at this stage. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at